New FDA Draft Guidance Encourages Industry Focus On Improving Clinical Trial Diversity - Life Sciences, Biotechnology & Nanotechnology
Last week, in the midst of the Biden Administration's coordinated release of more than 90 "Equity Action Plans" by various federal agencies, the FDA issued a new draft guidance on enhancing clinical trial diversity.
Source: mondaq.com
